Fires Seizures

Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. It is crucial for clinicians to exercise their independent medical judgment, consider individual patient circumstances, and consult the most current evidence-based guidelines and expert opinions when making patient care decisions. The practice of medicine is constantly evolving, and this content may not reflect the very latest developments.

---

Overview

• Definition: Febrile Infection-Related Epilepsy Syndrome (FIRES) is a catastrophic, acute-onset epilepsy syndrome characterized by new-onset refractory status epilepticus (NORSE) following a non-specific febrile illness in a previously healthy individual, typically without evidence of active central nervous system (CNS) infection or a known epileptic etiology. It is considered a subset of NORSE, specifically one with a preceding febrile illness. The term "FIRES" is often used interchangeably with "Acute Encephalopathy with Refractory, Repetitive Partial Seizures (AERRPS)" in some literature, though FIRES emphasizes the preceding fever.
• Epidemiology: FIRES is a rare syndrome, predominantly affecting children and adolescents, though adult cases have been reported. The exact incidence is unknown due to its rarity and diagnostic challenges, but it is estimated to be less than 1 per 1,000,000 per year. There is no clear gender or ethnic predilection.
• Classification: FIRES is classified as an acute symptomatic epilepsy syndrome. It is a distinct clinical entity within the broader spectrum of NORSE, which includes cases without a preceding febrile illness or clear cause.

Pathophysiology

• Mechanism: The exact pathophysiology of FIRES remains largely unknown, but it is hypothesized to be an immune-mediated disorder, possibly triggered by an infection in a genetically susceptible individual, leading to a profound inflammatory response within the brain. It is not caused by direct CNS infection.
  • Proposed mechanisms include:
    • Neuroinflammation: Evidence suggests a prominent role of pro-inflammatory cytokines (e.g., IL-1β, IL-6, TNF-α) and inflammatory cells. This inflammation is thought to lead to neuronal excitotoxicity, blood-brain barrier disruption, and persistent epileptogenesis.
    • Post-infectious autoimmune response: The febrile illness may trigger an autoimmune reaction against neuronal antigens, similar to some autoimmune encephalitides, though specific autoantibodies are typically absent in FIRES.
    • Genetic predisposition: While no single gene is causative, some studies suggest a polygenic predisposition involving genes related to immune response or neuronal excitability, but this is not consistently found.
    • Channelopathies: Some theories propose that an inflammatory cascade might alter ion channel function, leading to hyperexcitability, though direct evidence for this as a primary mechanism is limited.
• Risk Factors:
  • Preceding febrile illness: A non-specific febrile illness (often viral, upper respiratory tract or gastrointestinal) occurring 2 days to 2 weeks prior to seizure onset.
  • Age: Predominantly affects children and adolescents (median age 8-9 years), though adults can be affected.
  • Unknown genetic susceptibility: While not fully elucidated, genetic factors may play a subtle predisposing role.
• Protective Factors: None are currently known or established for FIRES.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Prodromal febrile illness: Preceding non-specific fever (often low-grade) for days to weeks.
  • Abrupt onset of status epilepticus (SE): Characterized by highly frequent, prolonged, and often multifocal or focal seizures, which rapidly become refractory to standard anti-seizure medications (ASMs).
  • Rapid neurological deterioration: Progressive decline in consciousness and development of focal neurological deficits (e.g., hemiparesis, aphasia).
• Early Signs:
  • Non-specific febrile illness (headache, malaise, vomiting).
  • Initial focal or generalized tonic-clonic seizures, rapidly escalating in frequency and duration.
• Advanced Signs:
  • Protracted status epilepticus, often requiring continuous intravenous anesthesia (e.g., midazolam, propofol, pentobarbital).
  • Coma, requiring mechanical ventilation.
  • Autonomic dysfunction (e.g., fluctuating blood pressure, heart rate irregularities, temperature dysregulation).
  • Signs of cerebral edema or increased intracranial pressure if severe.
• Atypical Presentations:
  • Less pronounced or absent preceding febrile illness (making it NORSE without clear FIRES criteria).
  • Subtler seizure semiology initially, progressing later to status epilepticus.
  • More indolent onset of seizures, though still progressing to refractoriness.

Physical Examination

• Inspection:
  • Signs of ongoing seizure activity (motor manifestations, altered consciousness, nystagmus, autonomic signs).
  • Evidence of systemic illness (fever, rash – though rare and non-specific in FIRES).
  • Respiratory compromise (hypoventilation, apnea) if in deep status epilepticus or due to medication effects.
  • Signs of injury from falls during seizures.
• Palpation:
  • General examination for signs of underlying systemic illness (e.g., lymphadenopathy, organomegaly – usually absent in FIRES).
• Special Tests:
  • Neurological examination: May reveal focal deficits (e.g., hemiparesis, gaze deviation, aphasia/dysarthria) in the post-ictal phase or if structural damage occurs. Deep tendon reflexes may be asymmetric. Plantar reflexes may be extensor. Meningeal signs are typically absent.

Diagnostic Approach

FIRES is a diagnosis of exclusion. Extensive workup is required to rule out other causes of status epilepticus.

History Taking

• Key Questions:
  • Detailed description of the preceding febrile illness (onset, duration, symptoms).
  • Precise seizure semiology (focal, generalized, focal to bilateral tonic-clonic, myoclonic, clonic, tonic, atonic, absence).
  • Onset, frequency, and duration of seizures; evolution to status epilepticus.
  • Response to initial anti-seizure medications.
  • Developmental history and prior neurological health.
  • Family history of epilepsy or autoimmune conditions.
  • Exposure to toxins or drugs.
• Red Flags:
  • Acute onset of highly refractory status epilepticus in a previously healthy child or adolescent.
  • Seizures persisting despite multiple ASMs at therapeutic doses.
  • Absence of a clear infectious (e.g., meningitis, encephalitis) or toxic-metabolic cause.
  • Rapid progression of neurological deficits.

Laboratory Tests

• First-Line: To rule out common causes of status epilepticus.
  • Complete Blood Count (CBC) with differential: May show mild leukocytosis, non-specific.
  • Electrolytes (Na, K, Cl, Bicarbonate), Glucose, Renal Function (BUN, Creatinine): To rule out metabolic encephalopathy.
  • Liver Function Tests (ALT, AST, Bilirubin): To rule out hepatic encephalopathy or drug-induced liver injury.
  • Blood Gas (ABG/VBG): Assess acid-base status and oxygenation.
  • C-Reactive Protein (CRP) & Erythrocyte Sedimentation Rate (ESR): Inflammatory markers, often elevated, supporting an inflammatory process.
  • Procalcitonin: Usually normal, helps rule out bacterial sepsis/meningitis.
  • Blood Cultures: To rule out bacteremia/sepsis.
  • Toxicology Screen (urine/serum): To rule out drug intoxication (prescribed or illicit).
  • Lumbar Puncture with Cerebrospinal Fluid (CSF) Analysis:
    • Cell count and differential: Typically normal or mildly elevated lymphocytes (<50 cells/uL). Pleocytosis >50 cells/uL usually points to infectious/inflammatory cause.
    • Protein: Normal or mildly elevated.
    • Glucose: Normal (CSF glucose/blood glucose ratio >0.6).
    • Microbiology (Gram stain, bacterial culture, viral PCR panel for common neurotropic viruses like HSV, VZV, enterovirus, CMV, HHV-6, EBV): Crucial to rule out infectious encephalitis/meningitis.
    • Oligoclonal bands (OCB) and IgG index: May be elevated in some autoimmune conditions, but often normal in acute phase of FIRES.
• Confirmatory: No single confirmatory test for FIRES. Diagnosis is based on clinical presentation and exclusion of other causes.
  • Autoimmune Encephalitis Panel (serum and CSF): To rule out treatable autoimmune encephalitides (e.g., anti-NMDA receptor, anti-LGI1, anti-CASPR2, anti-GABAA/B receptor antibodies). These are typically negative in FIRES.
  • Genetic testing: Broad epilepsy gene panels or whole-exome sequencing may be considered to rule out genetic epilepsies that can present with refractory status epilepticus (e.g., SCN1A, KCNQ2, POLG, etc.), although these are not typical for a de novo onset like FIRES.
  • Metabolic screen (urine organic acids, plasma amino acids, ammonia, lactate, acylcarnitine profile): To rule out inborn errors of metabolism.
• Monitoring:
  • Continuous EEG (cEEG): Essential for monitoring seizure activity, identifying subclinical seizures, evaluating treatment response, and assessing background activity.
  • Repeated inflammatory markers: CRP, ESR can be monitored to track inflammatory response.
  • Serum ASM levels: To ensure therapeutic levels are achieved and to avoid toxicity.

Imaging

• Recommended:
  • Brain Magnetic Resonance Imaging (MRI):
    • Initial MRI: Often normal in the acute phase of FIRES.
    • Subsequent MRI (days to weeks later): May show subtle, evolving changes, including:
      • Hippocampal edema (T2/FLAIR hyperintensity) in the acute phase.
      • Diffuse cortical signal changes, often bilateral and symmetric.
      • Later, chronic findings may include focal or diffuse brain atrophy, particularly of the hippocampi and temporo-parietal regions.
• Advanced:
  • Positron Emission Tomography (PET) / Single-Photon Emission Computed Tomography (SPECT): May be helpful in chronic stages or when localizing persistent seizure foci.
    • PET (FDG-PET): May show diffuse or focal hypermetabolism initially during active seizures, followed by widespread hypometabolism in the interictal chronic phase, particularly in areas of atrophy.
    • SPECT: Can show areas of increased perfusion during ictal phase and decreased perfusion during interictal phase.

Management

Management of FIRES is challenging and requires a multidisciplinary team approach, often in a pediatric or neurocritical care unit.

Acute Management

• Immediate:
  • Airway, Breathing, Circulation (ABCs): Secure airway, provide ventilatory support if needed. IV access for medication administration.
  • Initial seizure control:
    • First-line: Benzodiazepines: Lorazepam 0.1 mg/kg IV (max 4 mg/dose, repeat q5-10min up to 2-3 doses) or Diazepam 0.15-0.2 mg/kg IV (max 10 mg/dose, repeat q5-10min).
• Stabilization:
  • Continuous EEG monitoring: Crucial for detecting ongoing seizure activity and assessing treatment response.
  • Second-line ASMs (loading doses): If SE persists after benzodiazepines.
    • Fosphenytoin: 20 mg PE/kg IV (max 1500 mg PE/day), infused at max 3 mg PE/kg/min.
    • Levetiracetam: 20-60 mg/kg IV (max 4500 mg/day), infused over 15-30 min. Higher doses (up to 60 mg/kg) are increasingly used for refractory status.
    • Valproic Acid: 20-40 mg/kg IV (max 3000 mg/day), infused over 30 min.
    • Lacosamide: 10-15 mg/kg IV (max 400 mg/day), infused over 30-60 min.
• Emergency (Refractory Status Epilepticus): If seizures persist despite multiple ASMs.
  • Continuous IV anesthetic agents: Aim for burst suppression on EEG.
    • Midazolam infusion: 0.05-0.4 mg/kg/hr IV, after a bolus of 0.15-0.2 mg/kg.
    • Propofol infusion: 1-5 mg/kg/hr IV, after a bolus of 1-2 mg/kg.
    • Pentobarbital infusion: 1-5 mg/kg/hr IV, after a bolus of 5-15 mg/kg.
    • Ketamine: Increasingly considered for super-refractory SE. Bolus 0.5-2 mg/kg IV, then infusion 0.5-5 mg/kg/hr.

Chronic Management

• Pharmacological:
  • Long-term ASMs: Patients often require polytherapy with high doses of ASMs due to the highly refractory nature of FIRES-related epilepsy. Choices are empirical and often include levetiracetam, valproic acid, clobazam, phenobarbital, topiramate, lacosamide.
  • Ketogenic Diet (KD): Considered an important non-pharmacological adjunctive therapy for refractory epilepsy in FIRES. It should be initiated early (within weeks of onset of status) if tolerated. The mechanism is unknown but may involve neuroprotection and anti-inflammatory effects.
• Non-pharmacological:
  • Rehabilitation: Aggressive and early physical therapy, occupational therapy, and speech therapy are crucial to mitigate long-term neurological deficits.
  • Neurocognitive support: Educational and psychological support for cognitive and behavioral issues.
  • Palliative care: For cases with severe, irreversible neurological damage and poor prognosis.
• Monitoring:
  • Regular EEG: To assess seizure control and monitor for changes in background activity.
  • Neurodevelopmental/cognitive assessments: To track long-term outcomes and tailor rehabilitation.
  • ASM levels: To monitor therapeutic ranges and potential toxicity.
  • Nutritional monitoring: Especially if on ketogenic diet.

Treatment Algorithms

The management of FIRES is evolving, with an increasing emphasis on early immunomodulatory therapy alongside aggressive ASM treatment.

• First-Line:
  • Acute SE management: Benzodiazepines, followed by continuous infusions of ASMs (midazolam, propofol, pentobarbital) to achieve burst suppression on EEG.
  • Immunomodulatory therapy: Should be initiated early, often within days of SE onset, once infection is reasonably ruled out.
    • High-dose corticosteroids: Methylprednisolone 20-30 mg/kg/day IV (max 1000 mg/day) for 3-5 days. Often followed by oral prednisone taper.
    • Intravenous Immunoglobulin (IVIg): 2 g/kg total dose, administered over 2-5 days (e.g., 0.4 g/kg/day for 5 days).
    • Plasma Exchange (PLEX): 5-7 exchanges over 1-2 weeks.
    • Often a combination of these agents is used based on clinical response and physician preference.
• Second-Line: If first-line immunotherapies fail or initial response is insufficient.
  • Cyclophosphamide: 500-1000 mg/m² IV monthly.
  • Rituximab: 375 mg/m² IV weekly for 4 doses.
  • Tocilizumab (IL-6 receptor antagonist): Case reports suggest efficacy.
  • Anakinra (IL-1 receptor antagonist): Growing evidence for its use, especially in refractory cases, given the inflammatory hypothesis.
• Refractory Cases (Chronic Phase):
  • Ketogenic diet: A cornerstone of chronic management for its efficacy in refractory epilepsy.
  • Cannabidiol (CBD): Can be considered as an adjunctive therapy for drug-resistant epilepsy, though specific efficacy in FIRES is not well-established.
  • Vagus Nerve Stimulation (VNS): May be considered for patients with chronic drug-resistant epilepsy to reduce seizure frequency and severity.
  • Corpus Callosotomy: A palliative surgical option for severe generalized or secondarily generalized seizures, reducing seizure burden rather than curing.
  • Investigational therapies: Immunosuppressants like azathioprine or mycophenolate mofetil in long term, though less evidence.

Complications

• Common:
  • Drug-resistant epilepsy: Nearly all survivors develop chronic, highly refractory epilepsy, often with daily seizures.
  • Cognitive impairment: Severe to profound intellectual disability is common, affecting memory, language, and executive functions.
  • Behavioral disturbances: Aggression, hyperactivity, autism-like features.
  • Motor deficits: Spasticity, ataxia, dystonia, hemiparesis.
• Serious:
  • Protracted status epilepticus: Can lead to permanent brain damage, cerebral edema, and increased intracranial pressure.
  • Respiratory failure: Due to prolonged SE or high doses of ASMs requiring mechanical ventilation.
  • Aspiration pneumonia: From impaired consciousness and seizures.
  • Multiorgan dysfunction: Due to systemic effects of prolonged SE, inflammation, or medication side effects.
• Long-term:
  • Brain atrophy: Particularly in temporal lobes, reflecting neuronal loss.
  • Severe neurological disability: Requiring lifelong care and support.
  • Socioeconomic burden: Significant impact on family and healthcare systems.

Prognosis

• Factors:
  • Duration of status epilepticus: Longer duration of SE is associated with worse outcomes.
  • Response to acute treatment: Prompt control of SE and response to immunomodulatory therapies may improve prognosis.
  • Severity of acute encephalopathy: Deeper coma and more severe initial neurological deficits predict worse outcomes.
  • Age of onset: Younger age at onset might be associated with more severe developmental regression.
• Survival: Mortality rates for FIRES are reported to be 10-20%, primarily due to complications of prolonged status epilepticus and multiorgan failure.
• Quality of Life: Survivors typically face a significantly impaired quality of life due to severe cognitive deficits, behavioral problems, and drug-resistant epilepsy. Most require extensive support and care. Full neurological recovery is rare.

Prevention

• Primary: No known primary prevention strategies for FIRES as the etiology is unknown.
• Secondary: Early recognition and aggressive management of status epilepticus might theoretically mitigate some of the secondary brain injury, but preventing the development of FIRES itself is not possible. Rapid diagnosis and initiation of immunomodulatory therapy might limit the extent of brain damage.
• Tertiary:
  • Aggressive seizure control: To minimize seizure-related brain injury.
  • Early and intensive rehabilitation: To maximize functional outcomes and mitigate long-term disability.
  • Supportive care: Nutritional support, management of complications, psychological support for patients and families.

Special Populations

• Pediatric: FIRES primarily affects children and adolescents. The acute presentation is often more dramatic, and the long-term impact on neurodevelopment is profound. Treatment dosages must be weight-based.
• Geriatric: Extremely rare in the elderly. Presentation may be confused with other causes of acute encephalopathy or stroke.
• Pregnancy: N/A as FIRES typically affects younger individuals outside of reproductive age. If a rare case were to occur in pregnancy, management would involve balancing maternal and fetal risks of ASMs and immunotherapies.
• Comorbidities: The presence of pre-existing neurological or systemic comorbidities can complicate diagnosis and management, requiring careful consideration of drug interactions and potential exacerbation of underlying conditions. Management strategies need to be individualized.

Clinical Pearls

• Diagnostic:
  • "Diagnosis of Exclusion": Always rule out infectious (viral encephalitis, bacterial meningitis), toxic, metabolic, and autoimmune causes of status epilepticus before diagnosing FIRES.
  • EEG is paramount: Continuous EEG monitoring is essential for diagnosis, management, and prognostication. Look for multifocal, rhythmic activity, and progression to burst suppression under anesthesia.
  • Subtle fever: The preceding febrile illness can be mild and non-specific, so a high index of suspicion is required.
  • Normal initial MRI and CSF: Don't be fooled by initially normal findings; repeat imaging and CSF analysis may be warranted if clinical suspicion remains high.
• Treatment:
  • Aggressive and Early: Prompt and aggressive management of status epilepticus is critical. Delay can lead to irreversible brain damage.
  • Multimodal approach: Combine high-dose ASMs with early immunomodulatory therapies. Consider the inflammatory nature of the disease from the outset.
  • Ketogenic Diet: Seriously consider early initiation of ketogenic diet as a potent anti-seizure and potentially anti-inflammatory therapy in chronic management.
  • Don't forget rehabilitation: Early and sustained rehabilitation is crucial for long-term functional outcomes, even amidst acute medical instability.
• Pitfalls:
  • Delayed diagnosis: Attributing symptoms to common infections or underestimating the severity of seizures.
  • Under-treatment of SE: Not escalating ASM therapy aggressively enough or not initiating continuous infusions in a timely manner.
  • Hesitancy with immunomodulation: Delaying immune therapies while waiting for definitive diagnosis, when early intervention might be beneficial.
  • Ignoring long-term consequences: Not planning for extensive rehabilitation and supportive care needed for chronic drug-resistant epilepsy and neurocognitive deficits.

Recent Updates

• Guidelines: Consensus definitions and diagnostic criteria for NORSE/FIRES have been developed by international consortia, facilitating standardized diagnosis and research. There's an increasing push for earlier recognition and initiation of empiric immunomodulatory therapies.
• Evidence:
  • Growing evidence supports the role of neuroinflammation in FIRES, particularly involving cytokines like IL-1β and IL-6. This has led to the exploration of specific cytokine antagonists (e.g., anakinra, tocilizumab) in highly refractory cases, with promising anecdotal reports and case series.
  • The efficacy of the ketogenic diet in managing chronic refractory epilepsy in FIRES is increasingly recognized and recommended.
  • Research is ongoing to identify specific biomarkers for FIRES, which could aid in earlier diagnosis and guide targeted therapies.
• Controversies:
  • Optimal immunomodulatory regimen: The best combination, timing, and duration of immunotherapies remain areas of active research and debate.
  • Role of genetic factors: The precise contribution of genetic predisposition is still unclear, and routine broad genetic testing is not universally recommended in the acute phase unless specific syndromic features are present.
  • Predictors of outcome: More robust predictors are needed to guide prognosis and treatment intensity from the outset.

Key References

1. Guidelines:
   • Hirsch, L. J., et al. (2018). "New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives." Epilepsia, 59(4), 745-752. (Consensus statement on NORSE/FIRES)
   • Glauser, T., et al. (2016). "Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society." Neurology, 87(15), 1571-1582. (General status epilepticus guidelines, applicable for initial management)
2. Studies:
   • Van Baalen, A., et al. (2010). "Febrile infection-related epilepsy syndrome (FIRES): A consequence of multiorgan inflammation in the brain?" Epilepsia, 51(9), 1788-1796. (Early case series highlighting inflammatory aspects)
   • Xiao, B., et al. (2020). "Early application of anakinra in febrile infection-related epilepsy syndrome: A case series and literature review." Seizure, 82, 102-108. (Emerging evidence for targeted immunotherapy)
3. Reviews:
   • Nabbout, R. (2020). "Febrile infection-related epilepsy syndrome (FIRES): An update." Epileptic Disorders, 22(Suppl 1), S30-S39.
   • Shellhaas, R. A. (2018). "Febrile infection-related epilepsy syndrome (FIRES): Current concepts." Developmental Medicine & Child Neurology, 60(9), 856-860.
   • Specchio, N., et al. (2020). "Ketogenic diet in severe childhood epilepsies: From the molecular to the clinical." Seizure, 82, 60-70. (Review on KD in severe epilepsies including FIRES)